Mecamylamine API Manufacturers

Looking for Mecamylamine API 60-40-2?

Description:

Here you will find a list of producers, manufacturers and distributors of Mecamylamine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Mecamylamine 

Synonyms:

Versamine  

Cas Number:

60-40-2 

DrugBank number:

DB00657 

Unique Ingredient Identifier:

6EE945D3OK

Mecamylamine is a type of Nicotinic acid derivatives

Nicotinic acid derivatives are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that are derived from nicotinic acid, also known as niacin or vitamin B3. These derivatives possess unique chemical structures and pharmacological properties, making them valuable components in the development of various drugs and therapies.

Nicotinic acid derivatives play a significant role in the treatment of several medical conditions. They are commonly used in the management of dyslipidemia, a condition characterized by abnormal levels of cholesterol and triglycerides in the blood. By acting as lipid-lowering agents, these derivatives help regulate lipid metabolism and reduce the risk of cardiovascular diseases.

Furthermore, nicotinic acid derivatives exhibit vasodilatory effects, which enhance blood flow and oxygen delivery to tissues. This property makes them effective in treating peripheral vascular diseases such as intermittent claudication and Raynaud's phenomenon.

Pharmaceutical companies utilize the unique characteristics of nicotinic acid derivatives to develop drugs with targeted actions. These derivatives can be modified to enhance their bioavailability, potency, and stability, ensuring optimal therapeutic outcomes.

Researchers continue to explore the potential of nicotinic acid derivatives in other therapeutic areas, including neurodegenerative disorders and inflammatory diseases. Their diverse chemical structures and pharmacological activities make them promising candidates for drug discovery and development.

In conclusion, nicotinic acid derivatives are a vital subcategory of pharmaceutical APIs, contributing to the development of drugs used in dyslipidemia management, peripheral vascular diseases, and other therapeutic applications. Their versatile nature and potential for further exploration make them an essential focus of research and development in the pharmaceutical industry.

Mecamylamine (Nicotinic acid derivatives), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• Euticals from Italy, product country of origin Unknown

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.